Behavioral therapy in migraine: Expanding the therapeutic arsenal

Other authors

Institut Català de la Salut

[Mínguez-Olaondo A, Alves Días P] Neurology Department, Hospital Universitario Donostia-Osakidetza , Neuroscience Area, Biogipuzkoa Health Institute, Donostia, Spain. Athenea Neuroclinics, Donostia, Spain. Department of Medicine and Department of Physical Therapy, Faculty of Health Sciences, University of Deusto, Bilbao and San Sebastian, Spain. [López de Munáin E] Athenea Neuroclinics, Donostia, Spain. Psiquiatric Department, Hospital Bidasoa, Irún, Spain. [Grozeva V] Neurology Practice, Sofia, Bulgaria. [Laspra-Solís C] Department of Psychiatry and Clinical Psychology, University Clinic of Navarra, Madrid, Spain. [Martín Villalba I] Department of Neurology, Hospital Clínic i Provincial de Barcelona, Barcelona, Spain. [Vila-Pueyo M] Grup de Recerca de Cefalea i Dolor Neurològic, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Departament de Medicina, Universitat Autònoma de Barcelona, Bellaterra, Spain

Vall d'Hebron Barcelona Hospital Campus

Publication date

2024-11-20T09:27:20Z

2024-11-20T09:27:20Z

2024-12



Abstract

Disability; Migraine; Therapy


Discapacidad; Migraña; Terapia


Discapacitat; Migranya; Teràpia


Background and purpose The US Headache Consortium developed evidence-based guidelines for the treatment of migraine and found grade A evidence in support of behavior therapy (BT). Understanding the mechanisms of BT may improve the management of migraine and reduce its burden. Methods We performed a narrative review to define the current evidence of BT and determine its usefulness in migraine management. Results The information was obtained from 116 publications, with 56 of them retrieved through direct searches in PubMed (2011–2020) and the remainder selected by the authors to complete the content. BT might reduce migraine impact by decreasing the sympathetic nervous system's response to stress and increasing pain tolerance. Acting in headache-related surroundings can be improved, together with headache duration and self-efficacy. Applications such as mobile health and electronic health applications can help to carry out healthier lifestyle patterns. Regarding medication overuse, BT seems to be a good choice, with similar results to pharmacological prophylaxis. Advantages of using BT are the lack of adverse effects and the unrestricted use in children, where BT is postulated to be even more effective than the standardized pharmacopeia. Conclusions BT is an interesting tool that can be used as an add-on therapy in migraine. Through BT, the autonomy and empowerment of migraine patients is enhanced. BT may not cure migraine, but it could help to reduce pain severity perception, disability, and migraine impact, adding an emotive and cognitive approach to the perceptive role of pharmacopeia. Thus, a better approach in migraine, implementing specific therapeutic management, can improve migraine control.

Document Type

Article


Published version

Language

English

Publisher

Wiley

Related items

European Journal of Neurology;31(12)

https://doi.org/10.1111/ene.16414

Recommended citation

This citation was generated automatically.

Rights

Attribution 4.0 International

http://creativecommons.org/licenses/by/4.0/

This item appears in the following Collection(s)